Enhance apoptosis in combination with XL647, an inhibitor of multiple receptor tyrosine kinases including EGFR, HER2, and VEGFR, in pre-clinical tumor modelsIn a phase I study, low drug exposure was achieved and the trial was thus stopped. Here, ERBB2 is linked to neoplasm.